CREG vs CDTX vs ACAD vs PESI

For growth investors, ACADIA Pharmaceuticals Inc.

(ACAD) is the stronger pick with 11. 9% revenue growth year-over-year, versus -94. 5% for Cidara Therapeutics, Inc. (CDTX). ACADIA Pharmaceuticals Inc. (ACAD) offers the better valuation at 9. 9x trailing P/E (50. 9x forward), making it the more compelling value choice. Analysts rate Cidara Therapeutics, Inc. (CDTX) a "Buy" — based on 11 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Cidara Therapeutics, Inc.

(CDTX) delivered a total return of +450. 7%, compared to -99. 5% for Smart Powerr Corp. (CREG). Over 10 years, the gap is even starker: PESI returned +178. 6% versus CREG's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Cidara Therapeutics, Inc.

(CDTX) is the lower-risk stock at 0. 87β versus Perma-Fix Environmental Services, Inc. 's 1. 85β — meaning PESI is approximately 113% more volatile than CDTX relative to the S&P 500. On balance sheet safety, Cidara Therapeutics, Inc. (CDTX) carries a lower debt/equity ratio of 2% versus 9% for Perma-Fix Environmental Services, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), ACADIA Pharmaceuticals Inc.

(ACAD) is pulling ahead at 11. 9% versus -94. 5% for Cidara Therapeutics, Inc. (CDTX). On earnings-per-share growth, the picture is similar: ACADIA Pharmaceuticals Inc. grew EPS 68. 4% year-over-year, compared to -409. 5% for Cidara Therapeutics, Inc.. Over a 3-year CAGR, ACAD leads at 27. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

ACADIA Pharmaceuticals Inc.

(ACAD) is the more profitable company, earning 36. 5% net margin versus -133. 2% for Cidara Therapeutics, Inc. — meaning it keeps 36. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ACAD leads at 9. 8% versus -138. 1% for CDTX. At the gross margin level — before operating expenses — CDTX leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for PESI: 61.

1% to $18. 00.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Cidara Therapeutics, Inc.

(CDTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 87)). Smart Powerr Corp. (CREG) carries a higher beta of 1. 83 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CDTX: -16. 0%, CREG: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (CREG (Utilities) and CDTX (Healthcare) and ACAD (Healthcare) and PESI (Industrials)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: CREG is a small-cap quality compounder stock; CDTX is a small-cap quality compounder stock; ACAD is a small-cap deep-value stock; PESI is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.